products must be authorized via the centralised procedure. These include:

• Medicinal products derived from biotechnology processes.
• Advanced therapy medicinal products (ATMPs).
• Medicinal products for the treatment of certain diseases and conditions such as HIV, diabetes, and cancer.
• Orphan drugs seeking market authorization aimed at rare diseases.

Advisory Points: It is crucial to consult the EMA guidelines, which provide further clarity on the mandatory categories.

Documentation Requirements

Documentation is critical for the successful filing of an application under the centralised procedure. Companies are required to compile a comprehensive dossier encompassing data from all relevant studies, including non-clinical, clinical, and manufacturing processes. The Common Technical Document (CTD) format is typically employed, which consists of five modules:

1. Module 1: Administrative information and prescribing information specific to the EU.
2. Module 2: Summaries of the quality information (Q), preclinical information (P), and clinical information (C).
3. Module 3: Quality information, which provides detailed descriptions of the drug substance and finished product.
4. Module 4: Non-clinical study reports.
5. Module 5: Clinical study reports.

Key Documents to Include

Key documents among the above modules include:

• Risk Management Plan (RMP): Outlines the risk minimisation strategies.
• Clinical Study Protocols: Presenting an overview of clinical trial designs and methodologies.
• Stability Data: Essential for supporting shelf-life claims and proper storage conditions.

Review/Approval Flow

The review and approval process under the centralised procedure is distinctive due to its reliance on the EMA’s involvement. This includes several phases:

1. Submission: The application is submitted electronically to the EMA.
2. Validation: The EMA performs a validation check over the submitted documents to ensure completeness.
3. Assessment: This phase consists of evaluation by members of the Committee for Medicinal Products for Human Use (CHMP), where several iterations of questions may be posed to provide clarity and confirm data integrity.
4. Opinion: After assessment, the CHMP issues an opinion which can be either positive or negative; this opinion is then forwarded to the European Commission.
5. Decision: The final marketing authorisation decision lies with the European Commission, which usually follows the CHMP’s opinion.

Timelines and Expectations

The statutory timelines for the review process are generally around 210 days, excluding clock stops for additional information requests. Companies should anticipate interactions with the CHMP through formal questions and answers during the assessment phase, which may influence the overall timeline.

Common Deficiencies in Applications

Despite adherence to regulatory guidelines, many applications face common deficiencies that must be proactively addressed to enhance the likelihood of approval:

• Inadequate or Incomplete Data: Submissions must include complete study data that support safety, efficacy, and quality.
• Weak Risk Management Plans: A clear outline of risks associated with the medicinal product is expected. Failure to provide robust risk management and mitigation strategies can result in a negative opinion.
• Regulatory and Compliance Issues: Ensure compliance with the Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) regulations throughout the development process.

Strategies to Avoid Deficiencies

To navigate potential deficiencies, companies should implement the following strategies:

• Pre-submission Consultation: Engage in early dialogue with the EMA through the Scientific Advice procedure for guidance on data requirements.
• Comprehensive Internal Review: Conduct thorough internal reviews of all submitted documents before filing to identify and rectify gaps.
• Continuous Training: Ensure Regulatory Affairs professionals remain updated on evolving regulatory requirements and expectations.

RA-Specific Decision Points

Understanding key decision points in the regulatory submission process can greatly affect the strategy of RA professionals. Among such decision points are:

Variation vs. New Application

Deciding whether to file a variation or a new application is crucial for organizations. Variations may be submitted for post-authorisation changes, while a new application is warranted for significant changes that could impact the quality, safety, or efficacy of the product.

• Factors to Consider:
  • The degree of change in the product’s formulation or manufacturing process.
  • Impact on the product’s safety profile or efficacy data, requiring additional clinical data.
• Documentation for Variations: Submitting changes necessitates detailed justification, including bridging data to demonstrate that the changes do not affect the overall product profile.

Bridging Data Justifications

Bridging data is often required to demonstrate that data generated in one context can be extrapolated to support regulatory submissions in another context.

• Criteria for Justification:
  • Demonstrating scientific similarity between the new and existing data.
  • Providing a rationale that explains why existing data conveys the necessary information under applicable regulations.

Conclusion

The centralised procedure under EU law provides a streamlined process for marketing authorisation, yet it comes with specific legal requirements and documentation prerequisites. Regulatory Affairs professionals must be equipped with the knowledge of when this procedure is mandatory and when it can be a strategic choice. Ensuring compliance with relevant regulations and anticipating common deficiencies will significantly bolster success rates in obtaining marketing authorisation.

For further guidance on the centralised procedure, professionals are encouraged to reference official EMA documentation which can serve as a critical resource throughout the application process.